Exemplar Genetics

exemplargenetics.com

At Exemplar Genetics, we enable discovery by providing the vehicle to break new ground on the medical research frontier. Until now, researchers have lacked animal models that faithfully represent human diseases. As a result, a sizeable barrier has blocked progress in the discovery of human disease mechanisms; novel diagnostics, procedures, devices, prevention strategies and therapeutics; and the ability to predict in humans the efficacy of those next-generation procedures, devices, and therapeutics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

LUNAPHORE AND NUCLEAI ANNOUNCE A PARTNERSHIP TO PROVIDE AIPOWERED SPATIAL BIOLOGY ANALYSIS TO ACCELERATE DRUG DEVELOPMENT

Lunaphore and Nucleai | September 09, 2022

news image

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. “We are thrilled to announce the partnership with Lunaphore and...

Read More

Cell and Gene Therapy

PHYTOLON AND GINKGO BIOWORKS COLLABORATE TO TAKE BIOLOGICAL PRODUCTION OF VIBRANT FOOD COLORS TO THE NEXT LEVEL

Phytolon; Ginkgo Bioworks | February 28, 2022

news image

Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast. Under this partnership, Phytolon is leveraging Ginkgo's ability to engineer biology at scale to work together on the production of vibrant betalain pigments, the healthy and colorful compounds found in foods like beets and cactus fruit. The project aims to ...

Read More

Industry Outlook

MONTE ROSA THERAPEUTICS ADVANCES SECOND DEVELOPMENT CANDIDATE, MRT-6160, A NOVEL, HIGHLY SELECTIVE MOLECULAR GLUE DEGRADER TARGETING VAV1

Globenewswire | May 29, 2023

news image

Monte Rosa Therapeutics, Inc. a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases. “MRT-6160 is a potent, orally bioavai...

Read More

Medical

PFIZER AND BIONTECH BEGIN ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR FDA APPROVAL OF COVID-19 VACCINE IN THE U.S

Pfizer, BioNTech | May 10, 2021

news image

Pfizer Inc. and BioNTech SE confirmed today the filing of a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in people aged 16 and above. Companies will send data to help the BLA to the FDA on a rolling basis in the coming weeks, along with a proposal for Priority Review. If the BLA has been completed and duly approved for review by the FDA, the FDA will set a target date for a determination under the Prescr...

Read More
news image

Cell and Gene Therapy

LUNAPHORE AND NUCLEAI ANNOUNCE A PARTNERSHIP TO PROVIDE AIPOWERED SPATIAL BIOLOGY ANALYSIS TO ACCELERATE DRUG DEVELOPMENT

Lunaphore and Nucleai | September 09, 2022

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. “We are thrilled to announce the partnership with Lunaphore and...

Read More
news image

Cell and Gene Therapy

PHYTOLON AND GINKGO BIOWORKS COLLABORATE TO TAKE BIOLOGICAL PRODUCTION OF VIBRANT FOOD COLORS TO THE NEXT LEVEL

Phytolon; Ginkgo Bioworks | February 28, 2022

Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast. Under this partnership, Phytolon is leveraging Ginkgo's ability to engineer biology at scale to work together on the production of vibrant betalain pigments, the healthy and colorful compounds found in foods like beets and cactus fruit. The project aims to ...

Read More
news image

Industry Outlook

MONTE ROSA THERAPEUTICS ADVANCES SECOND DEVELOPMENT CANDIDATE, MRT-6160, A NOVEL, HIGHLY SELECTIVE MOLECULAR GLUE DEGRADER TARGETING VAV1

Globenewswire | May 29, 2023

Monte Rosa Therapeutics, Inc. a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases. “MRT-6160 is a potent, orally bioavai...

Read More
news image

Medical

PFIZER AND BIONTECH BEGIN ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR FDA APPROVAL OF COVID-19 VACCINE IN THE U.S

Pfizer, BioNTech | May 10, 2021

Pfizer Inc. and BioNTech SE confirmed today the filing of a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in people aged 16 and above. Companies will send data to help the BLA to the FDA on a rolling basis in the coming weeks, along with a proposal for Priority Review. If the BLA has been completed and duly approved for review by the FDA, the FDA will set a target date for a determination under the Prescr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us